



Published in final edited form as:

J Neuroophthalmol. 2012 March ; 32(1): 68–81. doi:10.1097/WNO.0b013e3182474548.

Shedding Light on Photophobia

Kathleen B. Digre, MD and

Departments of Ophthalmology and Neurology, University of Utah, Salt Lake City, Utah

K.C. Brennan, MD

Department of Neurology, University of Utah, Salt Lake City, Utah

Abstract

Photophobia is a common yet debilitating symptom seen in many ophthalmic and neurologic disorders. Despite its prevalence, it is poorly understood and difficult to treat. However, the past few years have seen significant advances in our understanding of this symptom. We review the clinical characteristics and disorders associated with photophobia, discuss the anatomy and physiology of this phenomenon, and conclude with a practical approach to diagnosis and treatment.

Keywords

photophobia; migraine; blepharospasm; melanopsin

Introduction

Photophobia is reported in most all forms of migraine and many neuro-ophthalmic disorders. The symptom is a hallmark of primary eye conditions such as uveitis as well as certain retinal dystrophies. It is included as one of the major criteria for migraine in International Classification of Headache Disorders (1, 2). It is listed as a major symptom in blepharospasm. Yet in other clinical settings, some have suggested that photophobia is merely a functional symptom without an organic basis (3).

Nomenclature of photophobia

The term photophobia is a misnomer and not quite accurate. It comes from two Greek words: photo- “light” and phobia “fear or dread of”—hence, “fear of light.” It is defined as an “abnormal sensitivity to light, especially of the eyes” (4). In defining photophobia nearly eight decades ago, Lebensohn (5) wrote “exposure of the eye to light definitely induces or exacerbates pain”.

There are other terms and concepts of light aversion that must be distinguished from photophobia. Cummings and Gittinger (6) described “central dazzle” as an uncomfortable, but not painful, sense of excessive brightness. They thought this represented a thalamic dysesthetic or hyperpathia syndrome. Loewenfeld (7) described “the dazzling syndrome” as abnormal light scatter without ocular adaptation. “Hemeralopia” or “day blindness” refers to

Address correspondence to: Kathleen B. Digre, MD, Departments of Ophthalmology and Neurology, University of Utah, 65 Mario Capecchi Drive, Salt Lake City, UT 84132; Kathleen.digre@hsc.utah.edu; telephone number: 801-585-6653. K.C. Brennan, MD, Department of Neurology, University of Utah, 383 Colorow Drive, Salt Lake City UT 84108; K.C.Brennan@hsc.utah.edu; telephone number: 801-581-8129.

Both authors contributed equally to this work.

Conflict of interest statement: The authors report no conflicts of interest.

blurring of vision due to light and is a frequent complaint in patients with retinal (e.g. cone dystrophy) and rarely optic nerve disorders. In these cases, patients report they see better in dim illumination (8). We have used the term “photo-oculodynia,” to describe pain or discomfort in the eye from a light source that is not usually painful (9). This term is in keeping with the literature that describes pain from a normally non-painful stimulus (e.g. cutaneous allodynia) (10, 11). In this review, we define photophobia broadly as a sensory state in which light causes discomfort in the eye or head; it may also cause an avoidance reaction without overt pain. We use photo-oculodynia to describe light-induced eye pain from a normally non-painful source (e.g. ambient lighting).

Conditions associated with photophobia (Table 1)

We performed a chart review of 111 adults (53 men: 58 women) and 36 children who were diagnosed in an eye clinic with “photophobia.” (12). A cause was found in the majority of adults, while a diagnosis could not be found in most of the children. One half of the adults were unemployed and about 25% felt that the symptom greatly affected their quality of life. Their most common ocular condition was dry eyes, while their most common neurological disorder was migraine. Other neurological conditions included depression, blepharospasm, and PSP.

Anterior segment disease such as iritis, cyclitis, and blepharitis has long been known to cause photophobia. Lebensohn (5) found that the more superficial the corneal lesion, the more severe the photophobia. These disorders are presumably due to direct irritation of the trigeminal afferents that innervate the cornea and eye. Dry eyes and dry eye syndrome are a common ocular cause of photophobia (13). Data suggest that dry eyes can eventually lead to a corneal neuropathy that may persist after the dry eyes have cleared (14). Rosenthal (15) proposed that if a patient has symptoms of dry eyes and photophobia, but the examination does not support the diagnosis of dry eyes, one should consider “corneal neuropathy until proven otherwise”. Rosenthal used corneal biomicroscopy to show changes in the structure of the corneal nerves of patients with dry eyes (15). Corneal neuropathy can be triggered by a variety of conditions including dry eyes, zoster keratitis, diabetic neuropathy, and chemotherapy (14, 15).

Posterior segment disease such as retinal dystrophies, retinitis pigmentosa, and cone dystrophies has been associated with photophobia. At times hemeralopia or frequent photopsias are the presenting symptoms. Prokofyeva et al. (16) reported that in addition to changes in visual acuity and night vision, photophobia was a frequent early symptom of retinal dystrophies and cone disorders. Photophobia may be one of the earliest signs of cone dystrophy before visual loss; and the diagnosis of malingering frequently can be made (17, 18). Patients with conditions such as Alström syndrome have photophobia from initial onset (19). It is appropriate to evaluate patients with photophobia for a retinal disorder if the cause of the photophobia is not apparent. If there are other visual symptoms such as visual loss, retinal disorders must be considered.

Intracranial conditions such as meningeal irritation from meningitis (20), sub-arachnoid hemorrhage (21), or pituitary tumors or apoplexy (22) cause photophobia, thought to be due to irritation of the basal meninges especially around the diaphragma sellae (3). This pain is mediated by branches of the first division trigeminal nerve which innervates the meninges (23).

Migraine is the most common neurologic disorder causing photophobia, which is one of the major diagnostic criteria for migraine according to the International Classification of Headache Disorders (1, 2). Up to 80% of migraine patients experience photophobia during

an attack (24). The recent ID Migraine validation study suggested that the presence of photophobia, disability, and nausea predicted migraine approximately 98% of the time (25).

Drummond (26) showed migraineurs were more light sensitive both during and between migraine attacks compared with non-migraine controls. Vanagaite et al. (27) reported that patients with migraine experience increased light sensitivity to progressively increased amounts of light during and between headache episodes compared with controls. They concluded that photophobia “seems to be an intrinsic property of migraineurs”. Furthermore, 30–60% of migraine attacks are triggered by light or glare (28). Different visual stimuli known to provoke migraine include sunlight, flickering from motion pictures, television, and fluorescent lights (28, 29). It has been postulated that migraine is associated with “visual pathway dysfunction” from retina to occipital lobes (30).

Migraine is not the only headache type associated with photophobia. Subjects with tension headache have more light sensitivity than controls (31). Unilateral photophobia has been reported with cluster headache, hemicrania continua, and other trigeminal autonomic cephalalgias (32, 33). In fact, the presence of unilateral photophobia is considered important in establishing the diagnosis of the trigeminal autonomic cephalalgias (32).

Traumatic brain injury (TBI) is commonly associated with photophobia. Acute TBI causes displacement, irritation, or injury of pain-sensitive intracranial structures, which likely accounts for both the headache and photophobia associated with brain injury (see below for possible pathophysiology). However, photophobia often remains after initial injury. There is an increased sensitivity to light in the subacute period (7–19 days) after head injury (34); and though most patients with mild head injury are improved after 6 months (35), those with post-concussive syndrome retain an increased sensitivity to light (36).

A large contribution to post-traumatic photophobia, especially chronic symptoms, may be due to the comorbidity of migraine-like headache after TBI. In a meta-analysis of pain conditions after TBI, headache prevalence was 57.8% (95% CI: 55.5, 60.2%) (37). A study examining affective symptoms (PTSD and depression) after mild TBI also found an independent association of TBI with headache (38). However, these large studies did not use International Classification of Headache Disorders criteria to define headache type, and thus the photophobia component is difficult to ascertain. A smaller study of returning Iraq and Afghanistan veterans did use International Classification of Headache Disorders criteria, and found a greater likelihood of migraine (which has photophobia as a diagnostic criterion) in veterans with more frequent injuries and abnormal findings on neurological and neuropsychological exams (39). Clearly, these data are not conclusive, and they speak to the need for more precise ascertainment of both photophobia and headache symptoms after TBI (40).

Blepharospasm is a focal dystonia associated with involuntary blinking, squeezing and closure of the eyelids. The cause is unknown but is thought to be due to an excitation/inhibition imbalance in brainstem blink reflex pathways (41). While it has long been known that blepharospasm is associated with photophobia, our understanding of this association is limited. In one large survey of blepharospasm patients, Anderson et al. (42) found that 80% reported aggravation of blepharospasm with bright lights, while driving, watching television or reading. In a survey of 316 blepharospasm patients, 94% reported light sensitivity; ambient lighting could provoke spasms about half of the time, but bright light provoked spasms almost all of the time (43). We studied 30 subjects with blepharospasm, 30 patients with a known photophobic state (migraine) and 30 controls with no history of migraine or blepharospasm (44). We found that patients with blepharospasm were as light sensitive as patients with migraine, and that both groups were more light sensitive than controls

Progressive Supranuclear Palsy (PSP) is associated with photophobia, and may be quite specific for the disorder; one study showed that the symptom of photophobia alone differentiated PSP from corticobasal degeneration (45). In a comparative study of PSP and Parkinson's disease, patients with PSP had photophobia more frequently (13/16 patients vs. 6/14) (46).

Psychiatric conditions

Photophobia has been reported in association with agoraphobia. Patients with agoraphobia frequently wear dark glasses and feel more relaxed in darkness. Light will frequently trigger anxiety reactions in these patients. In one study, illumination levels were normalized in agoraphobia patients that underwent successful cognitive behavioral therapy (47).

Seasonal affective disorder is treated by viewing light (48), but little literature exists about photophobia and depression. One case report of a woman with bipolar depression revealed that she used eye patches during her depressive phase, and she used her light sensitivity to predict when she would be entering a depressive phase (49). Gerbaldo and Thaker (50) reported that photophobia occurs in patients with "neurasthenia" (now known as chronic fatigue), bipolar depression, or seasonal depression. In contrast, patients with schizophrenia are known to have "sun-gazing" tendencies without any discomfort (50). In a study of bright light therapy for depression, photophobia as well as other ocular symptoms also decreased with phototherapy. This initially counterintuitive response, decrease in light aversion with light therapy, suggests a powerful influence of affective circuits on photophobia (51). Patients with anxiety and panic disorder also tend to have a lowered threshold of tolerance to light. The light threshold in these patients also responded to behavioral modifications and therapy (52). Given the comorbidity of these disorders with neuro-ophthalmic disease (especially migraine), one might expect an association. Clearly, more research is needed.

Is photophobia really a nonorganic symptom?

The "sunglasses sign" suggests factitious visual loss (53). Furthermore, photophobia is thought to accompany secondary gain, and a review of cases for an independent visual examination discounted this symptom as factitious (54). For many years, migraine and blepharospasm were thought to be functional disorders (55). Certainly, photophobia accompanies depression and anxiety (52); this can make patient interaction and management difficult. As already discussed, photophobia can be diagnosed in association with migraine, blepharospasm, PSP, depression and anxiety—all conditions with an anatomical and physiological basis, and for which many treatments now are available. As will be seen below, photophobia has a rich and growing neurobiology. While photophobia can undoubtedly be associated with factitious disorders, it is unlikely to be a purely 'psychiatric' symptom.

Anatomy and Pathophysiology of Photophobia

Trigeminal nociceptive innervation

Photophobia is intimately, likely inextricably, linked to pain sensation. The trigeminal nerve and its nuclei are the primary mediators of pain sensation to the head.

The eye—Afferents lie in the ophthalmic (V1) portion of the trigeminal ganglion transmit pain information from the eye. The conjunctiva, cornea, sclera, and uvea (iris, ciliary body, and choroid) are densely innervated with trigeminal fibers, and exquisitely sensitive to pain. Any painful stimulus to these areas (e.g. corneal abrasion, iritis, uveitis) invariably causes photophobia. In contrast, the retina is insensate, as evidenced by the lack of pain with retinal detachment, chorioretinitis, and nonarteritic anterior ischemic neuropathy (NAION). The

optic nerve does contain trigeminal afferents (not within the nerve, but within blood vessels, and dura) which cause pain associated with optic neuritis and arteritic anterior ischemic neuropathy (AAION) (56, 57).

The orbit—Other structures in the orbit are also pain sensitive. As would be expected, trigeminal V1 branches are nociceptive. Extraocular muscles have nociceptive afferents that travel along cranial nerves (CN) III, IV, and VI, leading to pain with oral myositis. The pain of diabetic third nerve palsy is not clearly understood but is likely due to nociceptive afferents within CN III or the extra-ocular muscles that it innervates. Orbital blood vessels are trigeminally-innervated and contribute to the pain of orbital inflammation and superior orbital fissure syndrome (56, 57).

Autonomic innervation

The eye and orbit are densely innervated by autonomic effectors, most of which course along branches of the trigeminal nerve. Though not formally considered autonomic in their own right, trigeminal ganglion neurons are effectors as well as sensors. When activated by a nociceptive stimulus, they release mediators – including calcitonin gene related peptide and nitric oxide. This positive feedback loop underlies the *trigemino-vascular reflex*, whereby trigeminally-innervated cranial vessels dilate after a nociceptive stimulus, perpetuating nociceptor activation. The *trigemino-autonomic reflex* is a true multi-synaptic reflex, involving activation of superior salivatory and Edinger-Westphal nuclei by collaterals from the trigeminal nucleus caudalis. Superior salivatory outputs activate parasympathetic effectors in the pterygopalatine ganglion, which dilate vessels, and in the ciliary ganglion, which mediate lacrimation. Edinger-Westphal outputs mediate pupillary constriction. The trigemino-vascular and trigemino-autonomic reflexes are thought to underlie the conjunctival injection, tearing, and periorbital pain of migraine and cluster headache, which are almost invariably also accompanied by photophobia (58–61).

The orbit is also densely innervated by sympathetic efferents. The short ciliary nerves carry sympathetic supply to the blood vessels in the orbit, and the long ciliary nerves supply sympathetic innervation to the pupil. The cornea also receives sympathetic innervations (62). Stimulation of the superior cervical ganglion in humans causes pain (63), and pharmacological blockade of this ganglion produces relief in patients with intractable facial pain who have failed trigeminal section (63).

These findings are consistent with the understanding of sympathetic influences on somatic pain, best demonstrated in complex regional pain syndromes (CRPS; CRPS I: reflex sympathetic dystrophy, CRPS II: causalgia). Usual treatment of CRPS involves sympathetic block to the involved limb. We reasoned that sympathetic blockade might analogously reduce ocular pain and photophobia. Six patients with severe photophobia underwent placebo-controlled superior cervical ganglion blockade. All had marked reductions in spontaneous and light-triggered pain using local anesthesia but not with saline placebo (9). A second study with 19 patients showed similar findings (64).

The blink reflex is commonly considered as a response to stimulation of the cornea or face, but it is also induced by light and auditory stimuli, and distant somatosensory stimuli (65, 66). Each stimulus-induced reflex has individual wiring features, though all have in common motor outflow through the seventh cranial nerve. The blink reflex is likely relevant to photophobia: photophobia causes an increase in blinking. Conversely, conditions associated with blinking abnormalities (blepharospasm, PSP) also are associated with photophobia (67). This two-way interaction (photophobia leads to blinking; blinking leads to photophobia) suggests that there is cross-talk between the different blink reflex pathways, at

least as regards the percept of photophobia. One likely location for this is the medullary laterobulbar reticular formation, which integrates sensory input prior to CN VII output (65).

The corneal blink reflex begins with unmyelinated afferents from ciliary branches of V1, which synapse in the trigeminal nucleus caudalis (TNC) (the first sensory relay in the central nervous system mediating pain sensation from the head). The supraorbital blink reflex involves mixed (myelinated and unmyelinated) afferents, which synapse in both TNC and the principal trigeminal nucleus. Blink reflex can also be elicited by stimulation of branches of the facial nerve; however, as it has a similar latency to trigeminally-evoked responses, it likely involves a similar circuit. Surprisingly little is known about the light-evoked blink reflex: it is assumed that visual pathways including retina, optic nerve, and olivary pretectal nucleus are involved (65, 66). The light-evoked blink reflex is consensual, and has a longer latency than the other blink reflexes; evidence that it is multi-synaptic. It is thought that tactile- or electrical-stimulation-induced blink reflex signals converge on the trigeminal dorsal horn and laterodorsal reticular formation. There are also direct connections between principal nucleus of CN V and the olivary pretectal nucleus, directly to CN VII. The relatively long latency of the consensual blink response to supraorbital stimulation, and the even longer latency of the light-evoked blink response, suggests that these direct connections may not be involved (65, 66, 68, 69).

The circuitry of the blink reflex is very likely a part of the photophobia response, given the increased blink rate in photophobic patients (70). Whether such circuit changes are causal, or a consequence of some other pathology, is unclear. Certainly in the case of blepharospasm, abnormalities in the blink reflex pathway could be of primary importance (41).

Light perception and photophobia

The cardinal stimulus for photophobia is light; thus, pathways of light perception must be involved. Interestingly, photophobia can be experienced without image formation, as documented in some blind patients (71–74).

Rods and cones are the primary light sensors in the eye. They transmit photo-signals via bipolar and amacrine cells to retinal ganglion cells which exit the orbit via the optic nerve. Most of these fibers travel to the lateral geniculate nucleus of thalamus and then to occipital cortex, mediating vision. However, some travel to the olivary pretectal nucleus, which via efferents in the Edinger-Westphal nucleus helps mediate pupillary constriction and accommodation. Others travel to the suprachiasmatic nucleus to help entrain the circadian cycle (75–78).

More recently, a separate set of photo-sensors have been identified (79–81). Termed intrinsically-photosensitive retinal ganglion cells (IPRGCs), these contain the photo-pigment melanopsin rather than rhodopsin. IPRGCs both detect light (in a non-image forming manner) and project the photo-signal to the olivary pretectal and suprachiasmatic nuclei. They are now considered more important than rods and cones for circadian photo-entrainment (82, 83). These cells are present in the retina (~1–3% of ganglion cells), but surprisingly have also been identified in the iris (84). Thus, the eye may be photo-sensitive in ways that we have not even suspected until recently.

Integration of light sensation with nociceptive and autonomic responses in photophobia

It is intuitive that photophobia has elements of light perception and pain, but what are the neural circuit correlates of this multisensory experience?

Photophobia circuits—Recent studies have begun to elucidate the functional pathways that mediate photophobia. Two distinct circuits have been identified, and at least a third is possible. Given the redundant and parallel nature of homeostatic networks, it is likely that these networks are interconnected, and interact with each other. It is also quite possible that more circuits remain to be discovered.

Okamoto et al. (85) recorded in the trigeminal nucleus caudalis (TNC) as they shone light into the eyes of anesthetized rats. They found that the firing rate of TNC neurons increased on light exposure, a finding whose simplest interpretation is a nociceptive response to light (or photophobia). They could eliminate this light-evoked nociceptive discharge by lidocaine injection into either the globe or the trigeminal ganglion, showing that both intraocular afferents and trigeminal neurons were required for the response. Next, via lidocaine injection into the superior salivatory nucleus (SSN) or injection of vasoconstrictors into the globe, they showed that parasympathetic efferents (likely causing ocular vasodilation) were involved. The circuit that emerges (Fig 1) is of retinal photodetectors (whether rod, cone, or IPRGC is unclear) activating SSN, which in turn evokes ocular vasodilation and activation of pain-sensing neurons on blood vessels.

Nosedá et al. (86) identified a completely different circuit. By injecting a viral tracer into the globe, they made the surprising finding that a population of IPRGCs make direct connections in thalamic nuclei *not* normally associated with vision. These nuclei, posterior, lateral posterior, and intergeniculates are associated with somatosensation and pain. Next, they recorded from these retinally-connected thalamic neurons, and found that they responded to painful stimulation of the dura as well as to light. The convergent input from trigeminal and retinal afferents on the same thalamic neurons makes them uniquely positioned to interpret light as a nociceptive signal. In a sense they can be considered ‘photophobia neurons.’ (Fig 1). Nosedá et al. further characterized the projection pattern of these thalamic neurons into cortex finding. They found processes in multiple regions, including visual, somatosensory, and association cortices. This projection pattern suggests a broadly distributed, multi-sensory and nociceptive response for photophobia.

The role of the thalamus in this proposed multisensory integration bears mention. The thalamus is a critical state- and gain-setting region in the brain. Its role as a relay for sensory information is well understood, but the concept of a relay implies that little processing occurs, and this is not the case. Both gain and precision of sensory signals are actively altered in thalamus (87). Moreover, as the work of Nosedá et al. (86) demonstrates, there is integration of different sensory pathways within the region. However, the role of the thalamus cannot be properly appreciated in isolation. There is massive reciprocal innervation between thalamus and cortex, making it is more physiologically realistic to consider sensory alterations as taking place in a ‘thalamocortical unit’ (88). This has been best demonstrated in the study of sleep and waking state-associated oscillations (89), but it is surely equally relevant for sensory responses, which are themselves significantly modulated by state (90). Future research about thalamic roles in photophobia will hopefully uncover this sort of dynamic interaction.

Photophobia without the optic nerve?—It may be that photophobia does not depend on any form of retinal phototransduction. Dolgonos et al. (91) measured trigeminal blink reflex by stimulating the supraorbital nerve in rats. They replicated the well-known finding that light potentiates (increases in amplitude) the trigeminal blink reflex. What was surprising was that this effect persisted after they sectioned the optic nerve, which should disconnect any photo-signal leaving the eye. The authors suggest that ‘associational ganglion cells’ either directly activate trigeminal nociceptors in the orbit, or indirectly activate them through effects on uveal blood flow. Another possible explanation, given the

recent discovery of melanopsin photoreceptors in the iris (84), is that these intrinsically photosensitive ganglion cells bypass the retina and optic nerve entirely, to activate nociceptors either inside or outside the globe.

Thus, there are at least two, and possibly three ways that light from the eye can activate pain circuits: through conventional rod and cone circuits, through IPRGCs, and through melanopsin-containing ganglion-type cells outside the retina. There are also at least two pathways light-based nociception can take when exiting the globe, either through optic nerve projections to the pretectal nucleus or direct connections to the thalamus. It is also possible that intra-ocular trigeminal afferents are directly activated by extra-retinal melanopsin-containing ganglion-like cells. A caveat about the extra-retinal pathway is that it may not be directly applicable in humans, as extra-retinal melanopsin-containing cells have not been conclusively demonstrated. Although many conventional concepts of photophobia have been challenged in the past few years, it still appears that ocular contents are necessary, as complete enucleation removes the photophobia response (73, 92).

Possible molecular targets in photophobia—The intracranial nociception involved in migraine prominently involves activity of the calcium gene related peptide (CGRP) receptor. As mentioned above, trigemino-vascular afferents both release and respond to CGRP, which is both pro-nociceptive and vasodilatory. Because of its prominent role, CGRP is a target for acute migraine treatment, and CGRP antagonists alleviate acute migraine (93, 94). Interestingly, mice with gain-of-function mutations in the CGRP signaling pathway demonstrate symptoms consistent with migraine. The most prominent of these is photophobia (95, 96).

CGRP binds a heterodimeric receptor formed of the CRLR and RAMP1 proteins, activating adenylate cyclase and cyclic AMP. Reuber et al. (97) generated mice with increased sensitivity to CGRP via insertion of a human RAMP1 protein at high expression levels (*nestin/hRAMP1* mice). These mice were no different from wild-type littermates in ocular anatomy, motor activity or anxiety. However, they had a significant increase in light aversion on intracerebroventricular CGRP injection compared to the same littermates. This difference in light aversion was blocked by treatment with a CGRP antagonist, showing that the behavior was mediated by CGRP receptor activity. It will be very interesting to see what elements of the photophobia circuits are altered in RAMP1 mutant mice. Insights gained could lead to anatomically specific targets for migraine treatment (98).

Photophobia circuit alterations in humans: Psychophysics of photophobia—It is clear that there are individual “thresholds” of light sensitivity even in normal people. Most studies that have looked at thresholds of light in individuals showed some normal variation (27). However, subjects with migraine and even tension-type and cervicogenic headache (27) have lower thresholds (27, 99). Light sensitivity may also vary by season. Vanagaite and colleagues found that migraine patients, and to a lesser extent controls, had lower pain thresholds to light in the winter months (November through January) than in the summer months (May through July). There also appears to be a ‘summation’ or ‘integration’ involved in photophobia. Wirtschafter et al. (100) showed that binocular viewing lowered the threshold of light whereas uniocular viewing raised the threshold. Finally, the perception of light brightness is dependent on the state of retinal adaptation (e.g. dark adaptation), as is readily appreciated when stepping from a darkened movie theater into the sunshine (101, 102).

The wavelength of light may also affect the photophobia percept. Main et al. (103) found that shorter wavelength (blue) light was more uncomfortable for subjects with migraine than for those with tension-type headache or controls. These investigators also reported that

longer wavelength (red) light was also less comfortable for subjects with migraine (103). Good et al. (29) found that visually provoked beta brain activity was suppressed by red light and enhanced with blue light in migraine patients, showing that the two wavelengths have different effects on cortical activity. The reasons for this difference, and the noxious nature of both blue and red light to migraineurs, are unclear. The fact that intrinsically photosensitive retinal ganglion cells are preferentially sensitive to blue light is intriguing (83, 104).

Light stimulation can increase pain in the trigeminal and cervical regions in migraineurs compared with normal controls. Kowacs et al. (105) performed pressure algometer readings over the head, before and after stimulation with light up to a discomfort threshold. All migraine subjects had reduced thresholds of light sensitivity, which was not unexpected, but they also had significant and sustained (beyond the second testing) lowering of pressure and pain sensitivity in both trigeminal and cervical sites. Controls did not exhibit this phenomenon.

Functional imaging of photophobia networks in humans—Functional neuroimaging allows the study of photophobia networks in awake humans. This is proving critical in confirming knowledge gained in laboratory animals, but more importantly has allowed unique insights into the conscious perception of photophobia.

Moulton et al. (106) performed BOLD fMRI recordings in an individual with photophobia associated with overuse of contact lenses. During the photophobic state, activation of the trigeminal ganglia, trigeminal nucleus caudalis, ventroposteromedial thalamus, and anterior cingulate gyrus occurred, but without photophobia, these structures were not activated. This pattern of activation suggests photophobia was perceived as a truly painful stimulus. Trigeminal ganglion, TNC, and ventroposteromedial thalamus are all relays in cranial nociception, and the anterior cingulate cortex is an element in the ‘pain matrix’, a network of cortical and subcortical structures activated during the conscious perception of pain (107).

In a series of patients with LASIK-induced photophobia, Malecaze et al. (108) found that light-induced BOLD fMRI activation was increased in the visual association cortex, compared with controls. This suggests that photophobia may involve alterations in cortical visual processing as well as pain networks (see below) (108).

The photophobia of blepharospasm has also been investigated with functional imaging. Emoto et al. (109) used 18fluorodeoxyglucose positron emission tomography (18FDG-PET) to compare blepharospasm patients with and without photophobia to controls. They found that blepharospasm patients with photophobia had significantly increased metabolic activity in the thalamus and dorsal midbrain compared to non-photophobic patients and controls. The regions with the largest differences between photophobic and non-photophobic patients were thalamic ventral anterior (VA) and ventral lateral (VL) nuclei and the superior colliculus. Interestingly, the non-photophobic patients showed significantly decreased activity in the superior colliculus compared to controls. Both patient groups, by virtue of their blepharospasm, had increased rates of blinking compared to controls. VA, VL, and superior colliculus are all involved in motor control, thus it is interesting that photophobic and non-photophobic patients – equally affected by the motor symptoms of blepharospasm – showed differential activity patterns. However, superior colliculus is also involved in ocular-related sensorimotor integration; the difference in its activity might be explained by greater nociceptor input in photophobic patients.

Photophobia networks in migraine—Migraine is the most common clinical disorder associated with photophobia. A particular advantage of migraine for the study of

photophobia is that (for most) the symptom is intermittent. The migraine patient can serve as his or her own control.

In addition to examining photophobia pathways in rodents (see above), Nosedá et al. (73) examined humans with migraine-associated photophobia. These patients were unusual in that they all had specific visual pathway defects. Those that had undergone enucleation did not experience increased headache pain on exposure to light, but those with an intact eye did confirm earlier clinical reports (70–74), as well as the laboratory work of Okamoto et al. (85), which showed that ocular afferents were necessary for photophobia. Other patients, who were legally blind but presumably retained some retinal function, had photophobia as a prominent symptom of their migraines. This also supported the findings of Nosedá et al. (86) that IPRGCs, not image-forming ganglion cells, were responsible for the photophobia phenotype.

Migraine is associated with alterations in cortical excitability (110), and visual aura can be directly correlated with occipital dysfunction (111, 112). Denuelle et al. (113) used ^{15}O positron emission tomography (PET) to examine the response to light during migraine, after treatment with sumatriptan, and interictally. They found that light levels which evoked pain during headache did not cause pain either interictally or after sumatriptan treatment, confirming migraine-induced photophobia. They found that their photophobia stimulus induced a significant increase in cortical blood flow during the migraine attack (before or after treatment) but not interictally. This shows that the occipital neurovascular response is more sensitive during attacks, and is likely involved in the photophobia response (114, 115). In a separate study, the same group examined migraine patients exclusively in the interictal period, and demonstrated that even at ‘baseline’ they had larger areas of occipital activation to visual stimulation, and visual stimulation paired with pain, compared to controls (114). Martin et al. (116) showed similar findings using BOLD fMRI, with increased area of occipital activation to light during migraine attacks. Though there were some differences between the studies, their combined results show that the migraine-associated photophobia response persists into the interictal period, suggesting long-lasting alterations in sensory gain. The findings of increased response to pain + light, compared to light alone, are consistent with animal work showing multisensory integration during the photophobia response (86).

Approach to the diagnosis of photophobia (Fig 2)

Before treating photophobia, one needs to be certain of the cause. Careful history, along with neurologic and neuro-ophthalmic examination including visual fields, is essential. Pituitary tumor, meningitis, and other intracranial processes can present with photophobia. If there are focal neurologic findings, MRI of the brain is indicated. Other central causes such as PSP should be considered. However, the most common causes are dry eyes, “corneal neuropathy” and migraine. Diagnosing dry eye can be difficult. Examination techniques should include examination of the tear film, tear film break-up time, corneal staining with Rose-Bengal or fluorescein, and Schirmer’s testing. Corneal neuropathy is also difficult to diagnose. We instill lidocaine eye drops, and if the pain and discomfort resolve, this diagnosis is possible. Rosenthal (15) believes corneal nerve imaging by confocal microscopy also may be helpful.

Diagnosing migraine should not be a problem when one looks for pain associated with photophobia, phonophobia, nausea and/or vomiting, as well as pain that worsens with activity. Blepharospasm is usually not a challenge to diagnose if one observes frequent blinking. However, reflex blepharospasm in response to bright light can be difficult to

identify. Look for squeezing of eyes, apraxia of eye lid opening, and involuntary eye closure to even moderate levels of light.

Screening for depression and anxiety is also important. We conducted a study in which patients with chronic photophobia and migraine had increased scores on measures of depression and anxiety, compared to patients with episodic photophobia with migraine and to controls without migraine or photophobia (117).

Treatment of photophobia

There are few neuro-ophthalmic problems that can be as vexing to treat for clinicians. Are there really any known treatments? Certainly there have been no major randomized controlled trials of treatment of photophobia. Most of the literature consists of case-reports and a few studies with small numbers of subjects.

Use and misuse of tinted lenses—One principal treatment is to decrease the dark adapted state. Patients with severe photophobia who wear darkly tinted lenses should be encouraged to reduce dark adaptation. Chronic darkness will increase the perception and pain of light sensitivity. Lebensohn (5) cautioned that “tinted glasses as a symptomatic remedy for chronic photophobia are to be condemned because of both their ineffectiveness and their habit forming tendency”. Wearing sunglasses to an eye clinic has led many physicians to consider the patient to have some type of psychiatric disorder, or at least to predict nonorganic visual loss (118, 119).

Some optical tints have been tried successfully to combat photophobia. Red-tinted contact lenses have been tested in individuals with photophobia due to cone disorders (120–124). However, red tint appears to exacerbate migraine-associated photophobia (103).

Sunglasses do make sense in the bright sunlight for patients with migraine, tension type headaches and those with light sensitivity. Some tints have been successful in migraine. Good et al. (29) found that FL-41 tint, a rose-colored tint, reduced migraine frequency in children by over one-half. Subjects reported a decrease in photophobia and glare in between attacks, but no change in the light sensitivity associated with the migraine attack. FL-41 tint filters 80% of short wavelength 50 or 60 Hz flicker that is seen with fluorescent lights. As flicker stimuli can be particularly noxious to patients with migraine (125), the authors reasoned that flicker reduction contributed to the reduction in headaches.

We studied FL-41 tinted lenses and found that they increased the threshold to discomfort in all subjects (controls, migraineurs, and patients with blepharospasm), but they did not differ from gray tinted lenses in reducing light sensitivity (44). To test whether patients preferred FL-41 tint over gray tinted spectacles, we performed a double cross-over study of subjects with blepharospasm using Gray and FL-41 tint. Patients preferred FL-41 tint over gray spectacles and patients felt that FL-41 significantly reduced their symptoms (70). We also tested the blink reflexes of patients who wore FL-41 tint or placebo pink lenses while reading under a standardized light source. We found that in blepharospasm patients, FL-41 tint greatly reduced the number of blinks and intensity of blinks (70).

Studies using fMRI suggest that there may be different physiological responses to spectrally-specific tints compared to neutral density filtering (which attenuates all wavelengths equally). Huang et al. (126) used precision ophthalmic tints that normalized cortical activation on fMRI, whereas gray lenses did not in patients with migraine. Why would red or pink tinted lenses show this effect? Red tints tend to block blue wavelengths, which more likely may induce photophobia (103).

Treatment of dry eyes—Aggressive treatment of dry eyes may be helpful. In blepharospasm, associated dry eyes are commonly treated with drops and ointments, and possible punctual plugs (127).

Anti-inflammatory drops have been tested in reducing light sensitivity after cataract surgery and have not been found to be helpful (128). Xylocaine has been used after cataract surgery without decrease in light sensitivity (129).

Dilating drops—Cycloplegics can be used to give some relief in patients with ocular inflammation. This is likely due to reduction in ciliary muscle spasm since papillary dilation actually increases light entering the eye.

Systemic medications—Sedatives (eg barbiturates) that reduce “trigeminal irritability” are helpful and allow for prolonged sleep and closed eyes (130). Treatment of migraine-associated photophobia with migraine preventive medications including beta-blockers, calcium channel blockers, and anti-convulsants is reasonable (96). Acute migraine should be treated with migraine specific medications that have been shown to reduce photophobia associated with an acute attack (96). To the extent that other photophobic disorders are due to dysfunctional excitation/inhibition balance, migraine preventives, especially of the antiepileptic class, might be considered. Systemic medications that have been anecdotally reported to reduce the pain associated with photophobia include gabapentin, and melatonin.

Given the alleviation of photophobia with antidepressants in patients with comorbid depression (49, 50), such treatment appears helpful. If anxiety and panic disorder are present, anxiolytics may be beneficial.

While the mainstay treatment of blepharospasm is botulinum toxin (127), clinicians have tried tricyclic antidepressants, baclofen, benzodiazepam, orphenadrine, carbidopa/levodopa, and fluoxetine (131).

If corneal neuropathy is suspected, Rosenthal suggests topical lacosamide, or systemic anticonvulsants such as gabapentin, pregabalin, or carbamazepine (15).

Procedures—Various techniques in difficult clinical settings have been described in treating photophobia. Injections to the supraorbital nerve have been reported to cause a reduction in light sensitivity (130). Alcohol (40–60%) injected into the orbit (1.5 cc) has been reported to be helpful in cases of ocular inflammation to reduce photophobia and did not influence visual acuity (132). In one series, the majority of individuals with whiplash induced cervicgia and photophobia found relief with trigger point injections (133). Botulinum toxin injection was found to reduce photophobia associated with post-traumatic headache (134) and is used to treat chronic migraine (135).

Sympathetic blockade was first reported by Magitot (136). Fine and Digre (9) showed that superior cervical blockade by lidocaine did improve light sensitivity in some patients with photophobia. This treatment may be best in patients who have had known injury to the anterior segment, and who experience continued photo-oculodynia despite complete resolution of the injury.

Acknowledgments

The authors thank Susan Schulman for her expert editorial assistance. We also thank Dr. Bradley Katz for his suggestions.

Funding: KBD was supported in part by an unrestricted grant from Research to Prevent Blindness, Inc., New York, New York, USA, to the Department of Ophthalmology and Visual Sciences, University of Utah. KCB was supported by NIH (NS059072, NS070084) and the National Headache Foundation.

References

1. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. *Cephalalgia*. 1988; 8 (Suppl 7):1–96.
2. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. *Cephalalgia*. 2004; 24:1–160.
3. Trobe JD. Photophobia in anterior visual pathway disease. *J Neuroophthalmol*. 2002; 22:1–2. [PubMed: 11937896]
4. Webster's New World Dictionary. Cleveland: The World Publishing Company; 1968.
5. Lebensohn J. The nature of photophobia. *Arch Ophthalmol*. 1934; 12:380–383.
6. Cummings JL, Gittinger JW Jr. Central dazzle. A thalamic syndrome? *Arch Neurol*. 1981; 38:372–374. [PubMed: 7236068]
7. Loewenfeld, I. *The Pupil: Anatomy, Physiology, and Clinical Applications*. Detroit: Wayne State University Press; 1993. The “dazzling” syndrome; p. 1200
8. Ohba N, Ohba A. Nyctalopia and hemeralopia: the current usage trend in the literature. *Br J Ophthalmol*. 2006; 90:1548–1549. [PubMed: 17114591]
9. Fine PG, Digre KB. A controlled trial of regional sympathectomy in the treatment of photo-oculodynia syndrome. *J Neuroophthalmol*. 1995; 15:90–94. [PubMed: 7550935]
10. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. *Brain*. 2000; 123 (Pt 8):1703–1709. [PubMed: 10908199]
11. Mathew NT, Kailasam J, Seifert T. Clinical recognition of allodynia in migraine. *Neurology*. 2004; 63:848–852. [PubMed: 15365135]
12. Buchanan T, Digre K, Warner JE, Katz BJ. A review of the symptom of photophobia in an eye clinic. *Neurology*. 2009; 72:A 184.
13. Pflugfelder SC. Tear Dysfunction and the Cornea: LXVIII Edward Jackson Memorial Lecture. *Am J Ophthalmol*. 2011; 152:900–909. e901. [PubMed: 22019306]
14. Benitez-Del-Castillo JM, Acosta MC, Wassfi MA, Diaz-Valle D, Gegundez JA, Fernandez C, Garcia-Sanchez J. Relation between corneal innervation with confocal microscopy and corneal sensitivity with noncontact esthesiometry in patients with dry eye. *Invest Ophthalmol Vis Sci*. 2007; 48:173–181. [PubMed: 17197530]
15. Karmel, M. [Accessed November 18, 2011] Addressing the pain of corneal neuropathy [online]. Available at: http://www.aao.org/publications/eyenet/201007/upload/29_CUcornea_FF_copy.pdf
16. Prokofyeva E, Troeger E, Wilke R, Zrenner E. Early visual symptom patterns in inherited retinal dystrophies. *Ophthalmologica*. 2011; 226:151–156. [PubMed: 21832827]
17. Zervas JP, Smith JL. Neuro-ophthalmic presentation of cone dysfunction syndromes in the adult. *J Clin Neuroophthalmol*. 1987; 7:202–218. [PubMed: 2963026]
18. Simunovic MP, Moore AT. The cone dystrophies. *Eye (Lond)*. 1998; 12 (Pt 3b):553–565. [PubMed: 9775217]
19. Russell-Eggitt IM, Clayton PT, Coffey R, Kriss A, Taylor DS, Taylor JF. Alstrom syndrome. Report of 22 cases and literature review. *Ophthalmology*. 1998; 105:1274–1280. [PubMed: 9663233]
20. Lamonte M, Silberstein SD, Marcellis JF. Headache associated with aseptic meningitis. *Headache*. 1995; 35:520–526. [PubMed: 8530275]
21. Welty TE, Horner TG. Pathophysiology and treatment of subarachnoid hemorrhage. *Clin Pharm*. 1990; 9:35–39. [PubMed: 2406101]
22. Kawasaki A, Purvin VA. Photophobia as the presenting visual symptom of chiasmal compression. *J Neuroophthalmol*. 2002; 22:3–8. [PubMed: 11937897]

23. Fricke B, Andres KH, Von Doring M. Nerve fibers innervating the cranial and spinal meninges: morphology of nerve fiber terminals and their structural integration. *Microsc Res Tech.* 2001; 53:96–105. [PubMed: 11301485]
24. Choi JY, Oh K, Kim BJ, Chung CS, Koh SB, Park KW. Usefulness of a photophobia questionnaire in patients with migraine. *Cephalalgia.* 2009; 29:953–959. [PubMed: 19298545]
25. Lipton RB, Dodick D, Sadovsky R, Kolodner K, Endicott J, Hettiarachchi J, Harrison W. A self-administered screener for migraine in primary care: The ID Migraine validation study. *Neurology.* 2003; 61:375–382. [PubMed: 12913201]
26. Drummond PD, Woodhouse A. Painful stimulation of the forehead increases photophobia in migraine sufferers. *Cephalalgia.* 1993; 13:321–324. [PubMed: 8242724]
27. Vanagaite J, Pareja JA, Storen O, White LR, Sand T, Stovner LJ. Light-induced discomfort and pain in migraine. *Cephalalgia.* 1997; 17:733–741. [PubMed: 9399002]
28. Vincent AJ, Spierings EL, Messinger HB. A controlled study of visual symptoms and eye strain factors in chronic headache. *Headache.* 1989; 29:523–527. [PubMed: 2793458]
29. Good PA, Taylor RH, Mortimer MJ. The use of tinted glasses in childhood migraine. *Headache.* 1991; 31:533–536. [PubMed: 1960058]
30. Chronicle EP, Mulleners WM. Visual system dysfunction in migraine: a review of clinical and psychophysical findings. *Cephalalgia.* 1996; 16:525–535. discussion 523. [PubMed: 8980853]
31. Drummond PD. A quantitative assessment of photophobia in migraine and tension headache. *Headache.* 1986; 26:465–469. [PubMed: 3781834]
32. Irimia P, Cittadini E, Paemeleire K, Cohen AS, Goadsby PJ. Unilateral photophobia or phonophobia in migraine compared with trigeminal autonomic cephalalgias. *Cephalalgia.* 2008; 28:626–630. [PubMed: 18422722]
33. Cittadini E, Goadsby PJ. Hemicrania continua: a clinical study of 39 patients with diagnostic implications. *Brain.* 2010; 133:1973–1986. [PubMed: 20558416]
34. Waddell PA, Gronwall DM. Sensitivity to light and sound following minor head injury. *Acta Neurol Scand.* 1984; 69:270–276. [PubMed: 6464666]
35. Vos PE, Battistin L, Birbamer G, Gerstenbrand F, Potapov A, Prevec T, Stepan ChA, Traubner P, Twijnstra A, Vecsei L, von Wild K. EFNS guideline on mild traumatic brain injury: report of an EFNS task force. *Eur J Neurol.* 2002; 9:207–219. [PubMed: 11985628]
36. Bohnen N, Twijnstra A, Wijnen G, Jolles J. Tolerance for light and sound of patients with persistent post-concussional symptoms 6 months after mild head injury. *J Neurol.* 1991; 238:443–446. [PubMed: 1779251]
37. Nampiaparampil DE. Prevalence of chronic pain after traumatic brain injury: a systematic review. *JAMA.* 2008; 300:711–719. [PubMed: 18698069]
38. Hoge CW, McGurk D, Thomas JL, Cox AL, Engel CC, Castro CA. Mild traumatic brain injury in U.S. Soldiers returning from Iraq. *N Engl J Med.* 2008; 358:453–463. [PubMed: 18234750]
39. Ruff RL, Ruff SS, Wang XF. Headaches among Operation Iraqi Freedom/Operation Enduring Freedom veterans with mild traumatic brain injury associated with exposures to explosions. *J Rehabil Res Dev.* 2008; 45:941–952. [PubMed: 19165684]
40. Neely ET, Midgette LA, Scher AI. Clinical review and epidemiology of headache disorders in US service members: with emphasis on post-traumatic headache. *Headache.* 2009; 49:1089–1096. [PubMed: 19583598]
41. Berardelli A, Rothwell JC, Day BL, Marsden CD. Pathophysiology of blepharospasm and oromandibular dystonia. *Brain.* 1985; 108 (Pt 3):593–608. [PubMed: 4041776]
42. Anderson RL, Patel BC, Holds JB, Jordan DR. Blepharospasm: past, present, and future. *Ophthalm Plast Reconstr Surg.* 1998; 14:305–317.
43. Judd R, Digre KB, Warner JE, Schulman S, Katz BJ. Shedding light on blepharospasm: a patient-researcher partnership approach to assessment of photophobia and impact on activities of daily living. *Neuro-Ophthalmology.* 2007; 31:49–54.
44. Adams WH, Digre KB, Patel BC, Anderson RL, Warner JE, Katz BJ. The evaluation of light sensitivity in benign essential blepharospasm. *Am J Ophthalmol.* 2006; 142:82–87. [PubMed: 16815254]

45. Cooper AD, Josephs KA. Photophobia, visual hallucinations, and REM sleep behavior disorder in progressive supranuclear palsy and corticobasal degeneration: a prospective study. *Parkinsonism Relat Disord.* 2009; 15:59–61. [PubMed: 18328771]
46. Hills, W.; Warner, JE.; Katz, BJ.; Chelune, G.; Foster, N.; Steffens, J.; Thulin, P.; Chin, S.; Digre, K. American Academy of Neurology. Chicago: 2008. Neuro-ophthalmic findings that may reliably differentiate progressive supranuclear palsy and Parkinson's disease.
47. Kellner M, Wiedemann K, Zihl J. Illumination perception in photophobic patients suffering from panic disorder with agoraphobia. *Acta Psychiatr Scand.* 1997; 96:72–74. [PubMed: 9259228]
48. Shirani A, St Louis EK. Illuminating rationale and uses for light therapy. *J Clin Sleep Med.* 2009; 5:155–163. [PubMed: 19968050]
49. Gerbaldo H. Depression and photophobic behavior. *Am J Psychiatry.* 1988; 145:1479–1480. [PubMed: 3189612]
50. Gerbaldo H, Thaker G. Photophilic and photophobic behaviour in patients with schizophrenia and depression. *Can J Psychiatry.* 1991; 36:677–679. [PubMed: 1773404]
51. Gallin PF, Terman M, Reme CE, Rafferty B, Terman JS, Burde RM. Ophthalmologic examination of patients with seasonal affective disorder, before and after bright light therapy. *Am J Ophthalmol.* 1995; 119:202–210. [PubMed: 7832227]
52. Bossini L, Fagiolini A, Valdagno M, Padula L, Hofkens T, Castrogiovanni P. Photosensitivity in panic disorder. *Depress Anxiety.* 2009; 26:E34–36. [PubMed: 19035364]
53. Bengtzen R, Woodward M, Lynn MJ, Newman NJ, Biousse V. The “sunglasses sign” predicts nonorganic visual loss in neuro-ophthalmologic practice. *Neurology.* 2008; 70:218–221. [PubMed: 18195266]
54. Schutz JS, Mavrakanas NA. The value of the ophthalmological independent medical examination: analysis of 344 cases. *Br J Ophthalmol.* 2009; 93:1371–1375. [PubMed: 19570769]
55. Weller M, Wiedemann P. Hysterical symptoms in ophthalmology. *Doc Ophthalmol.* 1989; 73:1–33. [PubMed: 2698334]
56. Burton, H. Somatic sensation from the eye. In: Hart, WM., editor. *Adler's Physiology of the Eye.* St. Louis: Mosby Year Book; 1992. p. 71-100.
57. Last, R. Eugene Wolff's *Anatomy of the Eye and Orbit.* 5. Philadelphia: W.B. Saunders; 1961.
58. Edvinsson L, Uddman R. Neurobiology in primary headaches. *Brain Res Brain Res Rev.* 2005; 48:438–456. [PubMed: 15914251]
59. Goadsby PJ, Charbit AR, Andreou AP, Akerman S, Holland PR. Neurobiology of migraine. *Neuroscience.* 2009; 161:327–341. [PubMed: 19303917]
60. Goadsby PJ. Pathophysiology of migraine. *Neurol Clin.* 2009; 27:335–360. [PubMed: 19289219]
61. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. *Nat Rev Neurosci.* 2011; 12:570–584. [PubMed: 21931334]
62. Marfurt CF. Sympathetic innervation of the rat cornea as demonstrated by the retrograde and anterograde transport of horseradish peroxidase-wheat germ agglutinin. *J Comp Neurol.* 1988; 268:147–160. [PubMed: 3360982]
63. Davis L, Pollock L. The rôle of the sympathetic nervous system in the production of pain in the head. *Arch Neurol Psychiatry.* 1932; 27:282–293.
64. McCann JD, Gauthier M, Morschbacher R, Goldberg RA, Anderson RL, Fine PG, Digre KB. A novel mechanism for benign essential blepharospasm. *Ophthalm Plast Reconstr Surg.* 1999; 15:384–389.
65. Esteban A. A neurophysiological approach to brainstem reflexes. Blink reflex. *Neurophysiol Clin.* 1999; 29:7–38. [PubMed: 10093816]
66. Yates SK, Brown WF. Light-stimulus-evoked blink reflex: methods, normal values, relation to other blink reflexes, and observations in multiple sclerosis. *Neurology.* 1981; 31:272–281. [PubMed: 7193820]
67. Bologna M, Agostino R, Gregori B, Belvisi D, Ottaviani D, Colosimo C, Fabbri G, Berardelli A. Voluntary, spontaneous and reflex blinking in patients with clinically probable progressive supranuclear palsy. *Brain.* 2009; 132:502–510. [PubMed: 19043083]
68. Pearce JM. Observations on the blink reflex. *Eur Neurol.* 2008; 59:221–223. [PubMed: 18230890]

69. Aramideh M, Ongerboer de Visser BW. Brainstem reflexes: electrodiagnostic techniques, physiology, normative data, and clinical applications. *Muscle Nerve*. 2002; 26:14–30. [PubMed: 12115945]
70. Blackburn MK, Lamb RD, Digre KB, Smith AG, Warner JE, McClane RW, Nandedkar SD, Langeberg WJ, Holubkov R, Katz BJ. FL-41 tint improves blink frequency, light sensitivity, and functional limitations in patients with benign essential blepharospasm. *Ophthalmology*. 2009; 116:997–1001. [PubMed: 19410958]
71. Siegwart K. Zur Frage nach dem Vorkommen and dem Wesen des Blednungsschmerzes. *Schweizmed Wechschr*. 1920; 50:1165.
72. Zaidi FH, Hull JT, Peirson SN, Wulff K, Aeschbach D, Gosley JJ, Brainard GS, Gregory-Evans K, Rizzo J, Czeisler CA, Foster RG, Lockley SW. Short-wavelength light sensitivity of circadian, pupillary, and visual awareness in humans lacking an outer retina. *Curr Biol*. 2007; 17:2122–2128. [PubMed: 18082405]
73. Nosedá R, Burstein R. Advances in understanding the mechanisms of migraine-type photophobia. *Curr Opin Neurol*. 2011; 24:197–202. [PubMed: 21467933]
74. Amini A, Digre K, Couldwell WT. Photophobia in a blind patient: An alternate visual pathway. Case report. *J Neurosurg*. 2006; 105:765–768. [PubMed: 17121141]
75. Guler AD, Ecker JL, Lall GS, Haq S, Altimus CM, Lido HW, Barnard AR, Cahill H, Badea TC, Zhao H, Hankins MW, Berson DM, Lucas RJ, Yau KW, Haltar S. Melanopsin cells are the principal conduits for rod-cone input to non-image-forming vision. *Nature*. 2008; 453:102–105. [PubMed: 18432195]
76. Wilhelm H. The pupil. *Curr Opin Neurol*. 2008; 21:36–42. [PubMed: 18180650]
77. Kardon R, Anderson SC, Damarjian TG, Grace EM, Stone E, Kawasaki A. Chromatic pupil responses: preferential activation of the melanopsin-mediated versus outer photoreceptor-mediated pupil light reflex. *Ophthalmology*. 2009; 116:1564–1573. [PubMed: 19501408]
78. Kawasaki A, Kardon RH. Intrinsically photosensitive retinal ganglion cells. *J Neuroophthalmol*. 2007; 27:195–204. [PubMed: 17895821]
79. Berson DM, Dunn FA, Takao M. Phototransduction by retinal ganglion cells that set the circadian clock. *Science*. 2002; 295:1070–1073. [PubMed: 11834835]
80. Hattar S, Liao HW, Takao M, Berson DM, Yau KW. Melanopsin-containing retinal ganglion cells: architecture, projections, and intrinsic photosensitivity. *Science*. 2002; 295:1065–1070. [PubMed: 11834834]
81. Do MT, Yau KW. Intrinsically photosensitive retinal ganglion cells. *Physiol Rev*. 2010; 90:1547–1581. [PubMed: 20959623]
82. Chen SK, Badea TC, Hattar S. Photoentrainment and pupillary light reflex are mediated by distinct populations of ipRGCs. *Nature*. 2011; 476:92–95. [PubMed: 21765429]
83. Schmidt TM, Chen SK, Hattar S. Intrinsically photosensitive retinal ganglion cells: many subtypes, diverse functions. *Trends Neurosci*. 2011; 34:572–580. [PubMed: 21816493]
84. Xue T, Do MT, Riccio A, Jiang Z, Hsieh J, Wang HC, Merbs SL, Welsbie DS, Yoshioka T, Weissgerber P, STolz S, Flockerzi V, Friechel M, Simon MI, Clapham DE, Yau KW. Melanopsin signalling in mammalian iris and retina. *Nature*. 2011; 479:67–73. [PubMed: 22051675]
85. Okamoto K, Thompson R, Tashiro A, Chang Z, Bereiter DA. Bright light produces Fos-positive neurons in caudal trigeminal brainstem. *Neuroscience*. 2009; 160:858–864. [PubMed: 19285114]
86. Nosedá R, Constandil L, Bourgeois L, Chalus M, Villanueva L. Changes of meningeal excitability mediated by corticotrigeminal networks: a link for the endogenous modulation of migraine pain. *J Neurosci*. 2010; 30:14420–14429. [PubMed: 20980599]
87. Hirata A, Aguilar J, Castro-Alamancos MA. Noradrenergic activation amplifies bottom-up and top-down signal-to-noise ratios in sensory thalamus. *J Neurosci*. 2006; 26:4426–4436. [PubMed: 16624962]
88. Llinas RR, Steriade M. Bursting of thalamic neurons and states of vigilance. *J Neurophysiol*. 2006; 95:3297–3308. [PubMed: 16554502]
89. Steriade M, McCormick DA, Sejnowski TJ. Thalamocortical oscillations in the sleeping and aroused brain. *Science*. 1993; 262:679–685. [PubMed: 8235588]

90. Nicoletis MA, Fanselow EE. Thalamocortical [correction of Thalamocortical] optimization of tactile processing according to behavioral state. *Nat Neurosci.* 2002; 5:517–523. [PubMed: 12037519]
91. Dolgonos S, Ayyala H, Evinger C. Light-induced trigeminal sensitization without central visual pathways: another mechanism for photophobia. *Invest Ophthalmol Vis Sci.* 2011; 52:7852–7858. [PubMed: 21896840]
92. Custer PL, Reistad CE. Enucleation of blind, painful eyes. *Ophthalm Plast Reconstr Surg.* 2000; 16:326–329.
93. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. *N Engl J Med.* 2004; 350:1104–1110. [PubMed: 15014183]
94. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, Koppen H, Winner PK. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. *Lancet.* 2008; 372:2115–2123. [PubMed: 19036425]
95. Russo AF, Kuburas A, Kaiser EA, Raddant AC, Recober A. A Potential Preclinical Migraine Model: CGRP-Sensitized Mice. *Mol Cell Pharmacol.* 2009; 1:264–270. [PubMed: 20336186]
96. Sprenger T, Goadsby PJ. Migraine pathogenesis and state of pharmacological treatment options. *BMC Med.* 2009; 7:71. [PubMed: 19917094]
97. Recober A, Kaiser EA, Kuburas A, Russo AF. Induction of multiple photophobic behaviors in a transgenic mouse sensitized to CGRP. *Neuropharmacology.* 2010; 58:156–165. [PubMed: 19607849]
98. Recober A, Kuburas A, Zhang Z, Wemmie JA, Anderson MG, Russo AF. Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine. *J Neurosci.* 2009; 29:8798–8804. [PubMed: 19587287]
99. Vanagaite Vingen J, Stovner LJ. Photophobia and phonophobia in tension-type and cervicogenic headache. *Cephalalgia.* 1998; 18:313–318. [PubMed: 9731934]
100. Wirtschafter JD, Bourassa CM, Dow RS. The quantitative study of photophobia. *Trans Am Neurol Assoc.* 1963; 88:291–293. [PubMed: 14275800]
101. Marks L. Brightness and equivalent intensity of intrinsic light. *Vision Res.* 1973; 13:371–382. [PubMed: 4692526]
102. Lamb TD, Pugh EN Jr. Dark adaptation and the retinoid cycle of vision. *Prog Retin Eye Res.* 2004; 23:307–380. [PubMed: 15177205]
103. Main A, Vlachonikolis I, Dowson A. The wavelength of light causing photophobia in migraine and tension-type headache between attacks. *Headache.* 2000; 40:194–199. [PubMed: 10759921]
104. Brainard GC, Sliney D, Hanifin JP, Glickman G, Byrne B, Greeson JM, Jassen S, Germa E, Rollag MD. Sensitivity of the human circadian system to short-wavelength (420-nm) light. *J Biol Rhythms.* 2008; 23:379–386. [PubMed: 18838601]
105. Kowacs PA, Piovesan EJ, Werneck LC, Tatsui CE, Lange MC, Ribas LC, da Silva HP. Influence of intense light stimulation on trigeminal and cervical pain perception thresholds. *Cephalalgia.* 2001; 21:184–188. [PubMed: 11442552]
106. Moulton EA, Becerra L, Borsook D. An fMRI case report of photophobia: activation of the trigeminal nociceptive pathway. *Pain.* 2009; 145:358–363. [PubMed: 19674842]
107. Legrain V, Iannetti GD, Plaghki L, Mouraux A. The pain matrix reloaded: a salience detection system for the body. *Prog Neurobiol.* 2011; 93:111–124. [PubMed: 21040755]
108. Malecaze FJ, Boulanouar KA, Demonet JF, Guell JL, Imbert MA. Abnormal activation in the visual cortex after corneal refractive surgery for myopia: demonstration by functional magnetic resonance imaging. *Ophthalmology.* 2001; 108:2213–2218. [PubMed: 11733261]
109. Emoto H, Suzuki Y, Wakakura M, Horie C, Kiyosawa M, Mochizuki M, Kawasaki K, Oda K, Ishiwata K, Ishii K. Photophobia in essential blepharospasm—a positron emission tomographic study. *Mov Disord.* 2010; 25:433–439. [PubMed: 20014062]
110. Coppola G, Pierelli F, Schoenen J. Is the cerebral cortex hyperexcitable or hyperresponsive in migraine? *Cephalalgia.* 2007; 27:1427–1439. [PubMed: 18034686]

111. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. *Ann Neurol*. 1981; 9:344–352. [PubMed: 6784664]
112. Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischi B, Kwang KK, Cotren FM, Rosen BR, Tootell RB, Sorensen AG, Moskowitz MA. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. *Proc Natl Acad Sci U S A*. 2001; 98:4687–4692. [PubMed: 11287655]
113. Denuelle M, Bouilloche N, Payoux P, Fabre N, Trotter Y, Geraud G. A PET study of photophobia during spontaneous migraine attacks. *Neurology*. 2011; 76:213–218. [PubMed: 21148120]
114. Bouilloche N, Denuelle M, Payoux P, Fabre N, Trotter Y, Geraud G. Photophobia in migraine: an interictal PET study of cortical hyperexcitability and its modulation by pain. *J Neurol Neurosurg Psychiatry*. 2010; 81:978–984. [PubMed: 20595138]
115. Brennan KC. Turn down the lights!: an irritable occipital cortex in migraine without aura. *Neurology*. 2011; 76:206–207. [PubMed: 21148117]
116. Martin H, Del Rio MS, de Silanes CL, Alvarez-Linera J, Hernandez JA, Pareja JA. Photoreactivity of the Occipital Cortex Measured by Functional Magnetic Resonance Imaging-Blood Oxygenation Level Dependent in Migraine Patients and Healthy Volunteers: Pathophysiological Implications. *Headache*. 2011; 51:1520–1528. [PubMed: 22082422]
117. Llop S, Frandsen F, Katz BJ, Warner JE, Digre K. Depression and anxiety in migraine patients with and without chronic photophobia. *Headache*. 2010; 50:S45.
118. Bruce BB, Newman NJ. Functional visual loss. *Neurol Clin*. 2010; 28:789–802. [PubMed: 20638000]
119. Howard RJ, Valori RM. Hospital patients who wear tinted spectacles--physical sign of psychoneurosis: a controlled study. *J R Soc Med*. 1989; 82:606–608. [PubMed: 2810299]
120. Marshall, JD.; Paisey, RB.; Carey, C.; Macdermott, S. Alstrom Syndrome. In: Pagon, RA.; Bird, TD.; Dolan, CR.; Stephens, K., editors. *GeneReviews* [Internet]. Seattle: University of Washington; 1993–2003 Feb 07. [updated 2010 Jun 08]
121. Rajak SN, Currie AD, Dubois VJ, Morris M, Vickers S. Tinted contact lenses as an alternative management for photophobia in stationary cone dystrophies in children. *J AAPOS*. 2006; 10:336–339. [PubMed: 16935234]
122. Michaelides M, Hunt DM, Moore AT. The cone dysfunction syndromes. *Br J Ophthalmol*. 2004; 88:291–297. [PubMed: 14736794]
123. Young RS, Krefman RA, Fishman GA. Visual improvements with red-tinted glasses in a patient with cone dystrophy. *Arch Ophthalmol*. 1982; 100:268–271. [PubMed: 6978127]
124. Park WL, Sunness JS. Red contact lenses for alleviation of photophobia in patients with cone disorders. *Am J Ophthalmol*. 2004; 137:774–775. [PubMed: 15059731]
125. Karanovic O, Thabet M, Wilson HR, Wilkinson F. Detection and discrimination of flicker contrast in migraine. *Cephalalgia*. 2011; 31:723–736. [PubMed: 21493642]
126. Huang J, Zong X, Wilkins A, Jenkins B, Bozoki A, Cao Y. fMRI evidence that precision ophthalmic tints reduce cortical hyperactivation in migraine. *Cephalalgia*. 2011; 31:925–936. [PubMed: 21622479]
127. Hallett M, Evinger C, Jankovic J, Stacy M. Update on blepharospasm: report from the BEBRF International Workshop. *Neurology*. 2008; 71:1275–1282. [PubMed: 18852443]
128. McDonald MB, Wyse TB, Borodkin MJ, Ocmant A, Shoelson B, Thompson H. Comparison of the effectiveness of 4 anti-inflammatory drops in relieving photophobia after pupil dilation. *J Cataract Refract Surg*. 1999; 25:405–410. [PubMed: 10079447]
129. Brierley L. Effect of lidocaine on photophobia. *J Cataract Refract Surg*. 1999; 25:1177. [PubMed: 10476495]
130. Lebensohn JE. Photophobia: mechanism and implications. *Am J Ophthalmol*. 1951; 34:1294–1300. [PubMed: 14877953]
131. Spencer BR Jr, Digre KB. Treatments for neuro-ophthalmologic conditions. *Neurol Clin*. 2010; 28:1005–1035. [PubMed: 20816275]
132. Hoyt, W. Walsh and Hoyt's *Neuro-Ophthalmology*. 3. Philadelphia: Lippincott Williams and Wilkens; 1969.

133. Freeman MD, Nystrom A, Centeno C. Chronic whiplash and central sensitization; an evaluation of the role of a myofascial trigger points in pain modulation. *J Brachial Plex Peripher Nerve Inj.* 2009; 4:2. [PubMed: 19389231]
134. Shoari M, Katz BJ. Treatment of the photo-oculodysnia syndrome with Botulinum toxin A. *Neuro-Ophthalmology.* 2007; 31:105–110.
135. Diener HC, Dodick DW, Aurora SK, Turkell CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. *Cephalalgia.* 2010; 30:804–814. [PubMed: 20647171]
136. Magitot A. Photophobie. *Ann D'ocul.* 1937; 174:917.
137. Tugal-Tutkun I, Araz B, Taskapili M, Akora YA, Yalniz-Alkaya Z, Berkeu N, Emie S, Gezer A. Bilateral acute depigmentation of the iris: report of 26 new cases and four-year follow-up of two patients. *Ophthalmology.* 2009; 116:1552–1557. 1557, e1551. [PubMed: 19545903]
138. Soeters MR, van Zeijl CJ, Boelen A, Kloos R, Saeed P, Vriesendorp TM, Mourits MP. Optimal management of Graves orbitopathy: a multidisciplinary approach. *Neth J Med.* 2011; 69:302–308. [PubMed: 21934174]
139. Enkvetchakul O, Thanathane O, Rangsin R, Lekhanont K, Suwan-Apichon O. A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: preliminary results. *Cornea.* 2011; 30:1213–1218. [PubMed: 21915047]
140. van der Veen RL, Fuijkschot J, Willemsen MA, Cruysberg JR, Berendschot TT, Theelen T. Patients with Sjogren-Larsson syndrome lack macular pigment. *Ophthalmology.* 2010; 117:966–971. [PubMed: 20163870]
141. Kaur H, Uy C, Kelly J, Moses AM. Orbital inflammatory disease in a patient treated with zoledronate. *Endocr Pract.* 2011; 17:e101–103. [PubMed: 21803720]
142. Alshami M, Bawazir MA, Atwan AA. Photoletter to the editor: A new variant of ichthyosis follicularis with alopecia and photophobia (IFAP) syndrome with coexisting psoriasiform lesions and palmoplantar keratoderma. IFAP-PPK syndrome? *J Dermatol Case Rep.* 2011; 5:14–16. [PubMed: 21886760]
143. Megarbane H, Megarbane A. Ichthyosis follicularis, alopecia, and photophobia (IFAP) syndrome. *Orphanet J Rare Dis.* 2011; 6:29. [PubMed: 21600032]
144. Carey, J. Trisomy 18 and Trisomy 13 syndromes. In: Cassidy, S.; Allanson, J., editors. *Management of Genetic Syndromes.* 3. Hoboken: Wiley-Blackwell; 2010. p. 807-825.
145. Yu HH, Yang TM, Shan YS, Lin PW. Zinc deficiency in patients undergoing pancreatoduodenectomy for periampullary tumors is associated with pancreatic exocrine insufficiency. *World J Surg.* 2011; 35:2110–2117. [PubMed: 21691869]




FIGURE 1. Photophobia circuits

1. Ganglion cells project light-related signaling to the olivary pretectal nucleus (OPN; light green). OPN projections activate superior salivatory nucleus (SSN; dark green), which via pterygopalatine ganglion, causes ocular vasodilation and activation of ocular trigeminal afferents (orange) which are heavily expressed on blood vessels. These afferents, with cell bodies in the trigeminal ganglion, project to trigeminal nucleus caudalis, thalamus and cortex. **2.** Intrinsically photosensitive retinal ganglion cells (IPRGCs) project directly to thalamic neurons (blue) that also receive intracranial nociceptive afferent signal (yellow neurons in trigeminal ganglion and trigeminal nucleus caudalis). Thalamic neurons fire in response to light and pain stimuli. Their output projects diffusely to sensory and association cortex. **3.** Melanopsin-containing, intrinsically photosensitive ganglion-like cells have been identified in rodent iris. These afferents may explain the fact that light can activate trigeminal blink reflex even after the optic nerve (through which circuits 1. and 2. pass) has been sectioned. Note that all three circuits may interact at different locations. (created from references 84–86, 91).




FIGURE 2.
An approach to the patient with photophobia.

Table 1**Conditions associated with photophobia****Ocular**

Anterior Segment:

- Ocular inflammation: (iritis, uveitis)
- Conjunctivitis
- Corneal diseases (corneal neuropathy, interstitial keratitis)
- Blepharitis
- Bilateral acute iris transillumination defects of the iris (137)
- Dry eyes

Dry eyes: the MOST Common cause of photophobia (including Grave's orbitopathy (138)

Pterygia (139)

Corneal neuropathy

Interstitial keratitis (Cogan's syndrome)

Posterior Segment:

- Vitritis
- Uveitis
- Photoreceptor dysfunction/retinal dystrophy (16)
- Albinism, achromatopsia, cone dystrophy, retinitis pigmentosa
- Alström Syndrome (19)
- Sjogren-Larsson Syndrome (140)
- Retinal dystrophy (16)

Optic Nerve

- Optic neuritis
- Papilledema

Chiasma

- Pituitary tumor (including apoplexy)
- Hypophysitis

Occipital lobe

- Hyperexcitability (113–115)

Neurologic

- Migraine
- Blepharospasm:
- Progressive supranuclear palsy
- Traumatic brain injury
- Meningeal irritation (meningitis, subarachnoid hemorrhage)

Thalamic Pathology (tumor, stroke, hemorrhage)**Psychiatric**

- Agoraphobia
- Anxiety disorder (panic disorder)
- Depression
- Hang-over headache

Medications

Barbiturates

Benzodiazepam

Chloroquine

Methylphenidate

Haldol

Zoledronate (141)

Other:

Neurasthenia (chronic fatigue)

Fibromyalgia

Measles

Rabies

Inflammatory bowel disease

IFAP syndrome (ichthyosis follicularis with alopecia and photophobia) PPK (psoriasiform lesions and palmoplantar keratoderma) (142, 143)

Trisomy 18 (144)

Zinc deficiency with exocrine insufficiency (145)
